Sandercock, P;
Lindley, R;
Wardlaw, J;
Dennis, M;
Innes, K;
Cohen, G;
Whiteley, W;
... IST-3 collaborative group; + view all
(2011)
Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.
Trials
, 12
, Article 252. 10.1186/1745-6215-12-252.
![]() Preview |
PDF
1745-6215-12-252.pdf Download (478kB) |
![]() |
PDF (Additional file 1: IST3 Protocol version 1_93 30th March 09_7 signed copy .pdf The current version of the trial protocol)
1745-6215-12-252-s1.pdf Download (479kB) |
![]() |
MS Word (Additional file 2: IST3 collabs list 141011. List of all collaborating centres and investigators with the number of patients recruited by each centre)
1745-6215-12-252-s2.doc Download (64kB) |
Abstract
Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for use in patients with acute ischaemic stroke who meet strictly defined criteria. IST-3 sought to improve the external validity and precision of the estimates of the overall treatment effects (efficacy and safety) of rtPA in acute ischaemic stroke, and to determine whether a wider range of patients might benefit.
Type: | Article |
---|---|
Title: | Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited |
Location: | England |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1186/1745-6215-12-252 |
Publisher version: | http://dx.doi.org/10.1186/1745-6215-12-252 |
Language: | English |
Additional information: | © 2011 Sandercock et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. PMCID: PMC3286387 |
Keywords: | Acute Disease, Brain Ischemia, Double-Blind Method, Fibrinolytic Agents, Humans, Prospective Studies, Sample Size, Stroke, Thrombolytic Therapy, Tissue Plasminogen Activator |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences |
URI: | https://discovery.ucl.ac.uk/id/eprint/1379040 |




Archive Staff Only
![]() |
View Item |